
Dr Kuerer on Selective Surgery Omission After Response to Neoadjuvant Therapy in Invasive Breast Cancer
Our 5-year analysis of the trial demonstrated that this new paradigm for the management of highly selected patients with HER2-positive and triple-negative breast cancer is both safe and effective." Henry M. Kuerer, MD, PhD, FACS, CMQ, a professor and …